Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing
暂无分享,去创建一个
Paul Maruff | Colin L. Masters | David Ames | Victor L. Villemagne | Christopher C. Rowe | Alan Rembach | Ralph N. Martins | Robert H. Pietrzak | Yen Ying Lim | C. Rowe | R. Martins | C. Masters | P. Maruff | D. Ames | R. Pietrzak | S. Laws | V. Villemagne | Y. Lim | K. Harrington | C. Restrepo | A. Rembach | Simon M. Laws | Karra Harrington | Carolina Restrepo
[1] Chris Corcoran,et al. Effects of family history and apolipoprotein E epsilon4 status on cognitive decline in the absence of Alzheimer dementia: the Cache County Study. , 2009, Archives of neurology.
[2] S. Leurgans,et al. Neurodegenerative basis of age-related cognitive decline , 2010, Neurology.
[3] Paul Maruff,et al. The association of Aβ amyloid and composite cognitive measures in healthy older adults and MCI , 2013, International Psychogeriatrics.
[4] F. Jessen,et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment , 2014, Alzheimer's & Dementia.
[5] C. Rowe,et al. Rapid decline in episodic memory in healthy older adults with high amyloid-β. , 2013, Journal of Alzheimer's disease : JAD.
[6] Olivier Salvado,et al. Incidence of cerebral microbleeds in preclinical Alzheimer disease , 2014, Neurology.
[7] Owen Carmichael,et al. Subgroup of ADNI normal controls characterized by atrophy and cognitive decline associated with vascular damage. , 2013, Psychology and aging.
[8] F. Jessen,et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. , 2010, Archives of general psychiatry.
[9] D. Bennett,et al. Cognitive decline in the elderly: an analysis of population heterogeneity. , 2011, Age and ageing.
[10] C. Rowe,et al. Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study , 2014, British Journal of Psychiatry.
[11] P. Snyder,et al. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease , 2014, Molecular Psychiatry.
[12] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[13] N. Foster,et al. Amyloid deposition and cognition in older adults: the effects of premorbid intellect. , 2013, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.
[14] Rebecca A Betensky,et al. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease , 2014, Neurology.
[15] Paul Maruff,et al. Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease. , 2013, Neuropsychology.
[16] F. Jessen,et al. Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease , 2012, Neurology.
[17] R. Snaith,et al. The Hospital Anxiety and Depression Scale , 1983 .
[18] D. G. Clark,et al. Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. , 2014, JAMA neurology.
[19] C. Jack,et al. Brain injury biomarkers are not dependent on β‐amyloid in normal elderly , 2013, Annals of neurology.
[20] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[21] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[22] George Jewell,et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study , 2014, Molecular Psychiatry.
[23] G. Alexander,et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.
[24] C. Rowe,et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.
[25] B. Muthén,et al. Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study , 2007 .
[26] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[27] T. Crook,et al. Assessment of Memory Complaint in Age-Associated Memory Impairment: The MAC-Q , 1992, International Psychogeriatrics.
[28] C. Rowe,et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults , 2012, Neurology.
[29] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[30] C. Jack,et al. Alzheimer's Disease Neuroimaging Initiative , 2008 .
[31] C. Rowe,et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. , 2014, Brain : a journal of neurology.
[32] C. Rowe,et al. Episodic memory decline predicts cortical amyloid status in community-dwelling older adults. , 2011, Journal of Alzheimer's disease : JAD.
[33] C. Rowe,et al. Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.
[34] A. Dale,et al. Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. , 2012, Archives of neurology.